9 severe adverse events to watch out for with checkpoint inhibitors
Pneumonitis is the leading cause of treatment-related death
The largest study yet of adverse events from checkpoint inhibitor therapy for cancer suggests doctors should be alert for nine serious adverse events.
The meta-analysis or more than 100 clinical trials and nearly 19,000 patients found one in seven cancer patients treated with either programmed cell death (PD-1) inhibitors or programmed cell death ligand-1 (PD-L1) inhibitors experienced a severe adverse event (grade 3 or worse according to National Cancer Institute criteria).
